These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 21405964)

  • 1. Progensa™ PCA3 test for prostate cancer.
    Durand X; Moutereau S; Xylinas E; de la Taille A
    Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
    J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
    Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
    Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
    J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCA3: from basic molecular science to the clinical lab.
    Day JR; Jost M; Reynolds MA; Groskopf J; Rittenhouse H
    Cancer Lett; 2011 Feb; 301(1):1-6. PubMed ID: 21093148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
    Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
    Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular PCA3 diagnostics on prostatic fluid.
    van Gils MP; Cornel EB; Hessels D; Peelen WP; Witjes JA; Mulders PF; Rittenhouse HG; Schalken JA
    Prostate; 2007 Jun; 67(8):881-7. PubMed ID: 17440939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
    Salagierski M; Schalken JA
    J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of urinary PCA3 test for prostate cancer diagnosis].
    Vlaeminck-Guillem V; Ruffion A; Andre J
    Prog Urol; 2008 May; 18(5):259-65. PubMed ID: 18538269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
    Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
    Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.
    van Gils MP; Hessels D; van Hooij O; Jannink SA; Peelen WP; Hanssen SL; Witjes JA; Cornel EB; Karthaus HF; Smits GA; Dijkman GA; Mulders PF; Schalken JA
    Clin Cancer Res; 2007 Feb; 13(3):939-43. PubMed ID: 17289888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
    Ploussard G; Haese A; Van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Bastien L; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; Van Gils MP; Schalken JA; de La Taille A
    BJU Int; 2010 Oct; 106(8):1143-7. PubMed ID: 20230386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster R; Andriole GL; Groskopf J
    J Urol; 2010 Nov; 184(5):1947-52. PubMed ID: 20850153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
    Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
    J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
    Chun FK; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Stillebroer AB; van Gils MP; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Haese A
    Eur Urol; 2009 Oct; 56(4):659-67. PubMed ID: 19304372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.
    de Kok JB; Verhaegh GW; Roelofs RW; Hessels D; Kiemeney LA; Aalders TW; Swinkels DW; Schalken JA
    Cancer Res; 2002 May; 62(9):2695-8. PubMed ID: 11980670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
    Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
    Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting.
    Adam A; Engelbrecht MJ; Bornman MS; Manda SO; Moshokoa E; Feilat RA
    BJU Int; 2011 Dec; 108(11):1728-33. PubMed ID: 21507188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.